Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.51 |
| ▸ | PRKAA2 | P54646 | 6/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.46 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.46 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.46 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.46 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.46 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6995086 | 0.83 | CCR3 (0.49) | CCR3PRKAA2MCHR1PRKAB2PRKAG1 | |
| SCHEMBL5314456 | 0.83 | EPHX2 (0.52) | EPHX2PRKAA2CHRM4CYP2C9CYP2C19 | |
| SCHEMBL7028488 | 0.82 | CD274 (0.61) | CCR3EPHX2CHRM4 | |
| SCHEMBL6996059 | 0.81 | CCR3 (0.49) | CCR3EPHX2CYP2C9CYP2C19CYP2J2 | |
| SCHEMBL6997557 | 0.79 | CCR3 (0.48) | CCR3EPHX2LMNA | |
| SCHEMBL7027153 | 0.79 | CCR3 (0.48) | CCR3LMNA | |
| SCHEMBL6995882 | 0.79 | DRD3 (0.52) | CCR3 | |
| SCHEMBL7033543 | 0.79 | CCR3 (0.48) | CCR3EPHX2LMNA | |
| SCHEMBL6995646 | 0.78 | DRD3 (0.56) | CCR3CYP2C9MCHR1LMNA | |
| SCHEMBL6997428 | 0.78 | DRD2 (0.41) | CCR3PRKAA2PRKAB2PRKAG1PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
| EP-1301510-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004446-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | CCR3 4291/4885EPHX2 3993/4885PRKAA2 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.